![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Alpha Tau Medical Ltd | NASDAQ:DRTS | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.02 | 0.95% | 2.13 | 2.13 | 2.15 | 2.13 | 2.10 | 2.10 | 5,606 | 19:33:13 |
|
State of Israel
|
| |
3841
|
|
|
(State or other jurisdiction of
incorporation or organization) |
| |
(Primary Standard Industrial
Classification Code Number) |
|
|
Nathan Ajiashvili
Eyal Orgad Latham & Watkins LLP 1271 Avenue of the Americas New York, New York 10020 Tel: (212) 906-1200 |
| |
Joshua G. Kiernan
Michael J. Rosenberg Latham & Watkins LLP 99 Bishopsgate London EC2M 3XF United Kingdom Tel: +44 (20) 7710-1000 |
| |
Shachar Hadar
Yoav Nahir Matthew R. Rudolph Meitar | Law Offices 16 Abba Hillel Silver Rd. Ramat Gan 5250608, Israel Tel: +972 (3) 610-3100 |
|
| | |
Page
|
| |||
FREQUENTLY USED TERMS
|
| | | | | | |
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
|
| | | | | | |
| | | | 1 | | | |
| | | | 7 | | | |
| | | | 9 | | | |
| | | | 14 | | | |
| | | | 21 | | | |
| | | | 25 | | | |
| | | | 32 | | | |
| | | | 35 | | | |
| | | | 36 | | | |
| | | | 40 | | | |
| | | | F-1 | | |
| | |
As of December 31, 2021
|
| |||||||||
| | |
Actual
|
| |
Pro
Forma |
| ||||||
Cash and cash equivalents
|
| | | $ | 23,236 | | | | | $ | 116,218 | | |
Restricted cash and short-term deposits
|
| | | | 8,698 | | | | | | 8,698 | | |
Warrants to convertible preferred shares
|
| | | | 18,623 | | | | | | — | | |
Warrant liability
|
| | | | — | | | | | | 10,137 | | |
Ordinary shares, no par value; 72,423,360 shares authorized; 40,528,913 issued and outstanding, actual; 275,000,000 shares authorized; 67,703,409 issued and outstanding, pro forma
|
| | | | — | | | | | | — | | |
Additional paid-in capital
|
| | | | 18,063 | | | | | | 178,080 | | |
Accumulated (deficit)
|
| | | | (52,840) | | | | | | (58,319) | | |
Total shareholders’ equity (deficiency)
|
| | | | (34,777) | | | | | | 119,761 | | |
Total capitalization
|
| | | $ | (34,777) | | | | | $ | 119,761 | | |
| | |
Purchase
Price |
| |
Shares
Issued |
| ||||||
HCCC public stockholders and Sponsor shares(1)
|
| | | $ | 10.00 | | | | | | 3,184,843 | | |
| | |
Shares
|
| |
%
|
| ||||||
Total Alpha Tau | | | | | | | | | | | | | |
Current Alpha Tau ordinary shareholders
|
| | | | 55,185,560 | | | | | | 81.6% | | |
HCCC Sponsor and other holders of founder shares(1)
|
| | | | 2,030,625 | | | | | | 3.0 | | |
HCCC public stockholders(1)
|
| | | | 1,154,218 | | | | | | 1.7 | | |
PIPE Investment
|
| | | | 9,251,006 | | | | | | 13.7 | | |
Total Alpha Tau Ordinary Shares Outstanding at Closing
|
| | |
|
67,621,409
|
| | | | | 100% | | |
| | |
As of
December 31, 2021 |
| |
Reflecting Actual Redemptions upon
Closing of the Business Combination on March 7, 2022 |
| ||||||||||||||||||||||||
| | |
Alpha Tau
Medical Ltd. (Historical) |
| |
Healthcare
Capital Corp. (Historical) |
| |
Transaction
Accounting Adjustments |
| | | | | | | |
Pro Forma
Combined |
| ||||||||||||
Assets | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
CURRENT ASSETS | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Cash and cash equivalents
|
| | | $ | 23,236 | | | | | $ | 557 | | | | | $ | 275,016 | | | | |
|
3A
|
| | | | $ | 116,218 | | |
| | | | | | | | | | | | | | | | | 92,510 | | | | |
|
3C
|
| | | | | | | |
| | | | | | | | | | | | | | | | | (9,513) | | | | |
|
3F
|
| | | | | | | |
| | | | | | | | | | | | | | | | | (2,130) | | | | |
|
3I
|
| | | | | | | |
| | | | | | | | | | | | | | | | | (263,458) | | | | |
|
3B
|
| | | | | | | |
Restricted cash
|
| | | | 618 | | | | | | — | | | | | | | | | | | | | | | | | | 618 | | |
Short-term deposits
|
| | | | 8,080 | | | | | | — | | | | | | | | | | | | | | | | | | 8,080 | | |
Prepaid expenses and other receivables
|
| | | | 707 | | | | | | — | | | | | | | | | | | | | | | | | | 707 | | |
Total current assets
|
| | |
|
32,641
|
| | | |
|
557
|
| | | |
|
92,425
|
| | | | | | | | | |
|
125,623
|
| |
Long-term assets:
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Long term prepaid expenses
|
| | | | 2,028 | | | | | | — | | | | | | | | | | | | | | | | | | 2,028 | | |
Property and equipment, net
|
| | | | 7,546 | | | | | | — | | | | | | | | | | | | | | | | | | 7,546 | | |
Marketable securities held in Trust Account
|
| | | | | | | | | | 275,016 | | | | | | (275,016) | | | | |
|
3A
|
| | | | | — | | |
Total long-term assets
|
| | | | 9,574 | | | | | | 275,016 | | | | | | (275,016) | | | | | | | | | | | | 9,574 | | |
Total assets
|
| | | $ | 42,215 | | | | | $ | 275,573 | | | | | $ | (182,591) | | | | | | | | | | | $ | 135,197 | | |
LIABILITIES, CONVERTIBLE PREFERRED SHARES AND SHAREHOLDERS’ DEFICIENCY
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
CURRENT LIABILITIES: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Trade payables
|
| | | $ | 1,203 | | | | | $ | — | | | | | | | | | | | | | | | | | $ | 1,203 | | |
Other payables and accrued expenses
|
| | | | 3,202 | | | | | | — | | | | | | | | | | | | | | | | | | 3,202 | | |
Accrued expenses
|
| | | | — | | | | | | 894 | | | | | | | | | | | | | | | | | | 894 | | |
Total current liabilities
|
| | | | 4,405 | | | | | | 894 | | | | | | | | | | | | | | | | | | 5,299 | | |
LONG-TERM LIABILITIES: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Warrants to convertible preferred shares
|
| | | | 18,623 | | | | | | — | | | | | | (18,623) | | | | |
|
3D
|
| | | | | — | | |
Deferred underwriting fee payable
|
| | | | | | | | | | 10,325 | | | | | | (10,325) | | | | |
|
3I
|
| | | | | — | | |
Warrant Liability
|
| | | | — | | | | | | 10,137 | | | | | | | | | | | | | | | | | | 10,137 | | |
Total liabilities
|
| | | | 23,028 | | | | | | 21,356 | | | | | | (28,948) | | | | | | | | | | | | 15,436 | | |
Commitments and contingencies | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Convertible preferred shares, NIS 0.00 par value per share
|
| | | | 53,964 | | | | | | — | | | | | | (53,964) | | | | |
|
3D
|
| | | |
|
—
|
| |
Class A common stock, subject to possible redemption at $10 per share
|
| | | | — | | | | | | 275,000 | | | | | | (275,000) | | | | |
|
3J
|
| | | | | — | | |
| | |
As of
December 31, 2021 |
| |
Reflecting Actual Redemptions upon
Closing of the Business Combination on March 7, 2022 |
| ||||||||||||||||||||||||
| | |
Alpha Tau
Medical Ltd. (Historical) |
| |
Healthcare
Capital Corp. (Historical) |
| |
Transaction
Accounting Adjustments |
| | | | | | | |
Pro Forma
Combined |
| ||||||||||||
Shareholders’ deficiency: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Ordinary shares, NIS 0.00 par value per share
|
| | | | — | | | | | | — | | | | | | | | | | | | | | | | | | — | | |
Class A common stock, $0.0001 par value
|
| | | | — | | | | | | — | | | | | | 1 | | | | |
|
3G
|
| | | | | — | | |
| | | | | | | | | | | | | | | | | (1) | | | | |
|
3E
|
| | | | | | | |
Class B common stock, $0.0001 par value
|
| | | | — | | | | | | 1 | | | | | | (1) | | | | |
|
3G
|
| | | | | — | | |
Additional paid-in capital
|
| | | | 18,063 | | | | | | — | | | | | | 275,000 | | | | |
|
3J
|
| | | | | 178,080 | | |
| | | | | | | | | | | | | | | | | 92,510 | | | | |
|
3C
|
| | | | | | | |
| | | | | | | | | | | | | | | | | 53,964 | | | | |
|
3D
|
| | | | | | | |
| | | | | | | | | | | | | | | | | 18,623 | | | | |
|
3D
|
| | | | | | | |
| | | | | | | | | | | | | | | | | (24,777) | | | | |
|
3E
|
| | | | | | | |
| | | | | | | | | | | | | | | | | (2,779) | | | | |
|
3F
|
| | | | | | | |
| | | | | | | | | | | | | | | | | 8,195 | | | | |
|
3I
|
| | | | | | | |
| | | | | | | | | | | | | | | | | 2,739 | | | | |
|
3H
|
| | | | | | | |
| | | | | | | | | | | | | | | | | (263,458) | | | | |
|
3B
|
| | | | | | | |
Accumulated deficit
|
| | | | (52,840) | | | | | | (20,784) | | | | | | 24,778 | | | | |
|
3E
|
| | | | | (58,319) | | |
| | | | | | | | | | | | | | | | | (6,734) | | | | |
|
3F
|
| | | | | | | |
| | | | | | | | | | | | | | | | | (2,739) | | | | |
|
3H
|
| | | | | | | |
Total shareholders’ deficiency
|
| | | | (34,777) | | | | | | (20,783) | | | | | | 175,321 | | | | | | | | | | | | 119,761 | | |
Total liabilities, convertible preferred shares and shareholders’ deficiency
|
| | | $ | 42,215 | | | | | $ | 275,573 | | | | | $ | (182,591) | | | | | | | | | | | $ | 135,197 | | |
|
| | |
For the Year Ended
December 31, 2021 |
| |
Reflecting Actual Redemptions upon Closing
of the Business Combination on March 7, 2022 |
| ||||||||||||||||||||||||
| | |
Alpha Tau
Medical Ltd. (Historical) |
| |
Healthcare
Capital Corp. (Historical) |
| |
Transaction
Accounting Adjustments |
| | | | | | | |
Pro Forma
Combined |
| ||||||||||||
Research and development, net
|
| | | $ | 11,447 | | | | | | — | | | | | $ | 1,735 | | | | |
|
3CC
|
| | | | $ | 13,182 | | |
Marketing expenses
|
| | | | 482 | | | | | | — | | | | | | 83 | | | | |
|
3CC
|
| | | | | 565 | | |
General and administrative
|
| | | | 1,861 | | | | | | — | | | | | | 6,734 | | | | |
|
3AA
|
| | | | | 9,516 | | |
| | | | | | | | | | | | | | | | | 921 | | | | |
|
3CC
|
| | | | | | | |
Formation and operating costs
|
| | | | — | | | | | | 1,930 | | | | | | | | | | | | | | | | | | 1,930 | | |
Total operating loss
|
| | | | 13,790 | | | | | | 1,930 | | | | | | 9,473 | | | | | | | | | | | | 25,193 | | |
Financial (income) expenses, net
|
| | | | 13,474 | | | | | | — | | | | | | | | | | | | | | | | | | 13,474 | | |
Change in fair value of warrants
|
| | | | — | | | | | | (12,193) | | | | | | | | | | | | | | | | | | (12,193) | | |
Transaction costs allocated to warrant liabilities
|
| | | | | | | | | | 851 | | | | | | | | | | | | | | | | | | 851 | | |
Fair value of warrant liability in excess of
purchase price paid for Private Place Warrants |
| | | | | | | | | | 680 | | | | | | | | | | | | | | | | | | 680 | | |
Interest earned on marketable securities held in Trust Account
|
| | | | | | | | | | (16) | | | | | | 16 | | | | |
|
3DD
|
| | | | | — | | |
Loss (income) before taxes on income
|
| | | | 27,264 | | | | | | (8,748) | | | | | | 1,294 | | | | | | | | | | | | 28,005 | | |
Tax on income
|
| | | | 7 | | | | | | — | | | | | | — | | | | |
|
3BB
|
| | | | | 7 | | |
Net loss (income)
|
| | | $ | 27,271 | | | | | $ | (8,748) | | | | | $ | 1,294 | | | | | | | | | | | $ | 28,012 | | |
Net loss per share of ordinary shares – basic and diluted
|
| | | $ | (0.67) | | | | | $ | (0.27) | | | | | | | | | | | | | | | | | $ | (0.42) | | |
Weighted average shares of ordinary shares outstanding – basic and diluted
|
| | | | 40,534,697 | | | | | | 25,993,151 | | | | | | | | | | |
|
4
|
| | | | | 66,807,020 | | |
Net loss per share – Class B – basic
|
| | | | | | | | | $ | (0.27) | | | | | | | | | | | | | | | | | | | | |
Weighted average shares outstanding – Class B – basic
|
| | | | | | | | | | 6,827,055 | | | | | | | | | | | | | | | | | | | | |
Net loss per share – Class B – diluted
|
| | | | | | | | | $ | (0.27) | | | | | | | | | | | | | | | | | | | | |
Weighted average shares outstanding – Class B – diluted
|
| | | | | | | | | | 6,875,000 | | | | | | | | | | | | | | | | | | | | |
Shareholders
|
| |
Reflecting Actual Redemptions
upon the Closing of the Business Combination |
| |||
U.S. dollars in thousands (except share and per share data) | | | | | | | |
Numerator | | | | | | | |
Net loss (in thousands)
|
| | | $ | (28,012) | | |
Denominator(1) | | | | | | | |
Former Alpha Tau ordinary shareholders and preferred shareholders
|
| | | | 54,273,883 | | |
HCCC Sponsor and other holders of founder shares(2)
|
| | | | 2,030,625 | | |
Former Sponsor shares forfeited and new shares allocated to the Alpha Tau Board and Management(3)
|
| | | | 97,288 | | |
HCCC public stockholders
|
| | | | 1,154,218 | | |
PIPE Investment | | | | | | | |
| | | | | 9,251,006 | | |
Total shares of Alpha Tau ordinary shares outstanding at closing of the Business Combination
|
| | | | 66,807,020 | | |
Net loss per share | | | | | | | |
Basic and diluted
|
| | | $ | (0.42) | | |
Name of Selling Security holders
|
| |
Number of
Ordinary Shares |
| |
Number of
Ordinary Shares Being Offered(1) |
| |
Number of
Ordinary Shares After Offering |
| |
Percentage of
Outstanding Ordinary Shares Owned After Offering |
| ||||||||||||
YOZMA EBEST GLOBAL MEDICAL FUND(2)
|
| | | | 1,650,000 | | | | | | 1,650,000 | | | | | | — | | | | | | — | | |
YOZMA KAI NEW GROWTH FUND NO. 1(3)
|
| | | | 50,000 | | | | | | 50,000 | | | | | | — | | | | | | — | | |
SJW INTERNATIONAL CO., LTD(4).
|
| | | | 200,000 | | | | | | 200,000 | | | | | | — | | | | | | — | | |
SIWON LEE(5)
|
| | | | 300,000 | | | | | | 300,000 | | | | | | — | | | | | | — | | |
HANMI HEALTHCARE, INC(6).
|
| | | | 1,000,000 | | | | | | 1,000,000 | | | | | | — | | | | | | — | | |
GRAND DECADE DEVELOPMENTS LIMITED(7)
|
| | | | 1,000,000 | | | | | | 1,000,000 | | | | | | — | | | | | | — | | |
RR INVESTMENT 2012, LP(8)
|
| | | | 263,677 | | | | | | 50,000 | | | | | | 213,677 | | | | | | * | | |
MARVIN DEN(9)
|
| | | | 25,000 | | | | | | 25,000 | | | | | | — | | | | | | — | | |
MORRY BLUMENFELD(10)
|
| | | | 199,387 | | | | | | 55,000 | | | | | | 144,387 | | | | | | * | | |
ISSACHAR KNOLL(11)
|
| | | | 276,323 | | | | | | 50,000 | | | | | | 226,323 | | | | | | * | | |
RONALD COHEN(12)
|
| | | | 1,103,300 | | | | | | 25,000 | | | | | | 1,078,300 | | | | | | 1.6% | | |
JOSEPH VENTURES ENTITIES(13)
|
| | | | 308,785 | | | | | | 127,500 | | | | | | 181,285 | | | | | | * | | |
MICHAEL AVRUCH(14)
|
| | | | 2,137,526 | | | | | | 50,000 | | | | | | 2,087,526 | | | | | | 3.0% | | |
GEORGETTE AVRUCH(15)
|
| | | | 762,178 | | | | | | 70,000 | | | | | | 692,178 | | | | | | 1.0% | | |
LINDA ADAMS(16)
|
| | | | 426,323 | | | | | | 200,000 | | | | | | 226,323 | | | | | | * | | |
RICHARD WOLFE(17)
|
| | | | 172,362 | | | | | | 60,000 | | | | | | 112,362 | | | | | | * | | |
ARIE KRAMER(18)
|
| | | | 136,148 | | | | | | 120,000 | | | | | | 16,148 | | | | | | * | | |
MEIR JAKOBSOHN(19)
|
| | | | 186,743 | | | | | | 75,000 | | | | | | 111,743 | | | | | | * | | |
ARIE JACOBSOHN(20)
|
| | | | 64,939 | | | | | | 25,000 | | | | | | 39,939 | | | | | | * | | |
MEDISON VENTURES LTD.(21)
|
| | | | 2,992,847 | | | | | | 200,000 | | | | | | 2,722,847 | | | | | | 4.0% | | |
FIELDCREST HOLDINGS LLC(22)
|
| | | | 50,000 | | | | | | 50,000 | | | | | | — | | | | | | — | | |
RINA MAZOZ(23)
|
| | | | 10,526 | | | | | | 6,000 | | | | | | 4,526 | | | | | | * | | |
GILA ASRAF(24)
|
| | | | 6,000 | | | | | | 6,000 | | | | | | — | | | | | | — | | |
OURCROWD ENTITIES(25)
|
| | | | 2,963,523 | | | | | | 299,999 | | | | | | 2,663,524 | | | | | | 3.9% | | |
THOMAS SCHMIDEK(26)
|
| | | | 543,234 | | | | | | 100,000 | | | | | | 443,234 | | | | | | * | | |
OHAD SHAKED(27)
|
| | | | 261,212 | | | | | | 225,000 | | | | | | 36,212 | | | | | | * | | |
HANNA ANNIE BATTASH(28)
|
| | | | 2,000 | | | | | | 2,000 | | | | | | — | | | | | | — | | |
SHMUEL RUBINSTEIN(29)
|
| | | | 24,195 | | | | | | 4,000 | | | | | | 20,195 | | | | | | * | | |
ALAN PATRICOF(30)
|
| | | | 236,485 | | | | | | 25,000 | | | | | | 211,485 | | | | | | * | | |
EDMUND SHAMSI(31)
|
| | | | 1,931,220 | | | | | | 160,000 | | | | | | 1,771,220 | | | | | | 2.6% | | |
HELENE SHAMSI(32)
|
| | | | 170,176 | | | | | | 140,000 | | | | | | 30,176 | | | | | | * | | |
KAEYO INVESTMENTS LTD.(33)
|
| | | | 7,500 | | | | | | 7,500 | | | | | | — | | | | | | — | | |
451WE ALPHA2 LLC(34)
|
| | | | 1,127,049 | | | | | | 500,000 | | | | | | 627,049 | | | | | | * | | |
MARAV MAZON KOL LTD.(35)
|
| | | | 500,000 | | | | | | 500,000 | | | | | | — | | | | | | — | | |
TZALIR PHARMA LTD.(36)
|
| | | | 8,000 | | | | | | 8,000 | | | | | | — | | | | | | — | | |
AVNER GOLDENBERG(37)
|
| | | | 795,783 | | | | | | 40,000 | | | | | | 755,783 | | | | | | 1.1% | | |
ROY GOLDENBERG(38)
|
| | | | 5,000 | | | | | | 5,000 | | | | | | — | | | | | | — | | |
KAMAREA LTD(39)
|
| | | | 5,000 | | | | | | 5,000 | | | | | | — | | | | | | — | | |
ARON TENDLER(40)
|
| | | | 479,161 | | | | | | 50,000 | | | | | | 429,161 | | | | | | * | | |
LIOR OPHIR(41)
|
| | | | 21,867 | | | | | | 1,672 | | | | | | 20,195 | | | | | | * | | |
Name of Selling Security holders
|
| |
Number of
Ordinary Shares |
| |
Number of
Ordinary Shares Being Offered(1) |
| |
Number of
Ordinary Shares After Offering |
| |
Percentage of
Outstanding Ordinary Shares Owned After Offering |
| ||||||||||||
DANIEL LAVINE(42)
|
| | | | 64,515 | | | | | | 12,121 | | | | | | 52,394 | | | | | | * | | |
STUART MINTZ(43)
|
| | | | 16,981 | | | | | | 5,000 | | | | | | 11,981 | | | | | | * | | |
CSINTALAN SANDOR(44)
|
| | | | 52,438 | | | | | | 6,000 | | | | | | 46,438 | | | | | | * | | |
DAN SPINER(45)
|
| | | | 28,018 | | | | | | 5,236 | | | | | | 22,782 | | | | | | * | | |
MAOZ LEV(46)
|
| | | | 138,109 | | | | | | 3,200 | | | | | | 134,909 | | | | | | * | | |
URI SALOMON(47)
|
| | | | 95,732 | | | | | | 1,000 | | | | | | 94,732 | | | | | | * | | |
DAVID GROVAS(48)
|
| | | | 7,284 | | | | | | 5,625 | | | | | | 1,659 | | | | | | * | | |
ORI GROVAS(49)
|
| | | | 5,723 | | | | | | 4,063 | | | | | | 1,660 | | | | | | * | | |
ADAM SOKOL(50)
|
| | | | 69,671 | | | | | | 13,090 | | | | | | 56,581 | | | | | | * | | |
DONGWOOK KO(51)
|
| | | | 40,000 | | | | | | 40,000 | | | | | | — | | | | | | — | | |
MIN SOO KIM(52)
|
| | | | 50,000 | | | | | | 50,000 | | | | | | — | | | | | | — | | |
JAE SANG YOO(53)
|
| | | | 50,000 | | | | | | 50,000 | | | | | | — | | | | | | — | | |
H. PIO CO., LTD.(54)
|
| | | | 512,000 | | | | | | 512,000 | | | | | | — | | | | | | — | | |
RU KA LUKE KANG(55)
|
| | | | 30,000 | | | | | | 30,000 | | | | | | — | | | | | | — | | |
DANIEL MARTIN CO., LTD.(56)
|
| | | | 100,000 | | | | | | 100,000 | | | | | | — | | | | | | — | | |
ABBA M. KRIEGER(57)
|
| | | | 10,000 | | | | | | 10,000 | | | | | | — | | | | | | — | | |
ESTER PORAT(58)
|
| | | | 426,344 | | | | | | 30,000 | | | | | | 396,344 | | | | | | * | | |
CHAN SOO KIM(59)
|
| | | | 40,000 | | | | | | 40,000 | | | | | | — | | | | | | — | | |
MINSU YU(60)
|
| | | | 10,000 | | | | | | 10,000 | | | | | | — | | | | | | — | | |
BIG MOVE VENTURES, CO. LTD.(61)
|
| | | | 100,000 | | | | | | 100,000 | | | | | | — | | | | | | — | | |
KIM JONG SEON(62)
|
| | | | 156,000 | | | | | | 156,000 | | | | | | — | | | | | | — | | |
NURIFLEX, CO., LTD.(63)
|
| | | | 200,000 | | | | | | 200,000 | | | | | | — | | | | | | — | | |
NURIVISTA, CO., LTD.(63)
|
| | | | 200,000 | | | | | | 200,000 | | | | | | — | | | | | | — | | |
NURIBILL, CO., LTD.(63)
|
| | | | 200,000 | | | | | | 200,000 | | | | | | — | | | | | | — | | |
Expenses
|
| |
Amount
|
| |||
SEC registration fee
|
| | | $ | 25,990 | | |
FINRA filing fee
|
| | | | * | | |
Transfer agent’s fee
|
| | | | * | | |
Printing and engraving expenses
|
| | | | * | | |
Legal fees and expenses
|
| | | | * | | |
Accounting fees and expenses
|
| | | | * | | |
Miscellaneous costs
|
| | | | * | | |
Total
|
| | | $ | * | | |
| Audited Financial Statements of Alpha Tau Medical Ltd. | | | | | | | |
| | | | | F-2 | | | |
| | | | | F-3 | | | |
| | | | | F-4 | | | |
| | | | | F-5 | | | |
| | | | | F-6 | | | |
| | | | | F-7 | | | |
| Audited Financial Statements of Healthcare Capital Corp. | | | | | | | |
| | | | | F-30 | | | |
| | | | | F-31 | | | |
| | | | | F-32 | | | |
| | | | | F-33 | | | |
| | | | | F-34 | | | |
| | | | | F-35 | | |
| | | | | | | | |
December 31,
|
| |||||||||
| | |
Note
|
| |
2020
|
| |
2021
|
| |||||||||
ASSETS
|
| | | | | | | | | | | | | | | | | | |
CURRENT ASSETS: | | | | | | | | | | | | | | | | | | | |
Cash and cash equivalents
|
| | | | | | | | | $ | 15,598 | | | | | $ | 23,236 | | |
Restricted cash
|
| | | | | | | | | | 576 | | | | | | 618 | | |
Short-term deposits
|
| | | | | | | | | | 30,417 | | | | | | 8,080 | | |
Prepaid expenses and other receivables
|
| | | | 3 | | | | | | 864 | | | | | | 707 | | |
Total current assets
|
| | | | | | | | | | 47,455 | | | | | | 32,641 | | |
Long-term assets: | | | | | | | | | | | | | | | | | | | |
Long term prepaid expenses
|
| | | | | | | | | | 139 | | | | | | 2,028 | | |
Property and equipment, net
|
| | | | 4 | | | | | | 5,395 | | | | | | 7,546 | | |
Total long-term assets
|
| | | | | | | | | | 5,534 | | | | | | 9,574 | | |
Total assets
|
| | | | | | | | | $ | 52,989 | | | | | $ | 42,215 | | |
LIABILITIES, CONVERTIBLE PREFERRED SHARES AND SHAREHOLDERS’ DEFICIENCY
|
| | | | | | | | | | | | | | | | | | |
CURRENT LIABILITIES: | | | | | | | | | | | | | | | | | | | |
Trade payables
|
| | | | | | | | | $ | 964 | | | | | $ | 1,203 | | |
Other payables and accrued expenses
|
| | | | 5 | | | | | | 1,124 | | | | | | 3,202 | | |
Total current liabilities
|
| | | | | | | | | | 2,088 | | | | | | 4,405 | | |
LONG-TERM LIABILITIES: | | | | | | | | | | | | | | | | | | | |
Warrants to convertible preferred shares
|
| | | | 7 | | | | | | 5,366 | | | | | | 18,623 | | |
Total liabilities
|
| | | | | | | | | | 7,454 | | | | | | 23,028 | | |
Commitments and Contingencies
|
| | | | 6 | | | | | | | | | | | | | | |
Convertible Preferred shares of no-par value per share – Authorized: 25,348,176 shares as of December 31, 2020 and 2021; Issued and outstanding: 13,739,186 shares as of December 31, 2020 and 2021;(*)
|
| | | | 9 | | | | | | 53,964 | | | | | | 53,964 | | |
Shareholders’ deficiency: | | | | | | | | | | | | | | | | | | | |
Ordinary shares of no-par value per share — Authorized: 72,423,360 shares as
of December 31, 2020 and 2021; Issued and outstanding: 40,433,578 and 40,528,913 shares as of December 31, 2020 and 2021, respectively;(*) |
| |
10
|
| | | | — | | | | | | — | | | |||
Additional paid-in capital
|
| | | | | | | | | | 17,140 | | | | | | 18,063 | | |
Accumulated deficit
|
| | | | | | | | | | (25,569) | | | | | | (52,840) | | |
Total shareholders’ deficiency
|
| | | | | | | | | | (8,429) | | | | | | (34,777) | | |
Total liabilities, convertible preferred shares and shareholders’ deficiency
|
| | | | | | | | | $ | 52,989 | | | | | $ | 42,215 | | |
| | | | | |
Year ended December 31,
|
| |||||||||||||||
| | |
Note
|
| |
2019
|
| |
2020
|
| |
2021
|
| |||||||||
Research and development, net
|
| | | | | | $ | 6,636 | | | | | $ | 7,544 | | | | | $ | 11,447 | | |
Marketing expenses
|
| | | | | | | 397 | | | | | | 288 | | | | | | 482 | | |
General and administrative
|
| | | | | | | 977 | | | | | | 1,412 | | | | | | 1,861 | | |
Total operating loss
|
| | | | | | | 8,010 | | | | | | 9,244 | | | | | | 13,790 | | |
Financial (income) expenses, net
|
| |
11
|
| | | | 308 | | | | | | (520) | | | | | | 13,474 | | |
Loss before taxes on income
|
| | | | | | | 8,318 | | | | | | 8,724 | | | | | | 27,264 | | |
Tax on income
|
| | | | | | | 146 | | | | | | 158 | | | | | | 7 | | |
Net loss
|
| | | | | | $ | 8,464 | | | | | $ | 8,882 | | | | | $ | 27,271 | | |
Less: net loss attributable to noncontrolling interests
|
| | | | | | $ | 97 | | | | | $ | — | | | | | $ | — | | |
Net loss attributable to Alpha Tau Medical Ltd.
|
| | | | | | $ | 8,367 | | | | | $ | 8,882 | | | | | $ | 27,271 | | |
Net loss per share attributable to ordinary shareholders,
basic and diluted |
| | | | | | | (0.25) | | | | | | (0.22) | | | | | | (0.67) | | |
Weighted-average shares used in computing net loss per
share attributable to ordinary shareholders, basic and diluted (*) |
| | | | | | | 33,815,448 | | | | | | 40,274,935 | | | | | | 40,534,697 | | |
| | |
Convertible
Preferred Shares |
| | | | |
Additional
paid-in capital |
| |
Accumulated
deficit |
| |
Nom
controlling interest |
| |
Total
Deficit |
| ||||||||||||||||||||||||||||||
|
Ordinary
Shares |
| |||||||||||||||||||||||||||||||||||||||||||||||
| | |
Shares
|
| |
Amount
|
| |
Shares
|
| |
Amount
|
| ||||||||||||||||||||||||||||||||||||
Balances as of January 1, 2019(*)
|
| | | | 7,229,885 | | | | | $ | 25,238 | | | | | | 33,185,538 | | | | | $ | — | | | | | $ | 9,330 | | | | | $ | (8,320) | | | | | $ | 851 | | | | | $ | 1,861 | | |
Share-based compensation
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 546 | | | | | | — | | | | | | — | | | | | | 546 | | |
Issuance of ordinary shares and warrants to ordinary shares
|
| | | | — | | | | | | — | | | | | | 1,302,132 | | | | | | — | | | | | | 5,250 | | | | | | — | | | | | | — | | | | | | 5,250 | | |
Exercise of warrants to ordinary shares
|
| | | | — | | | | | | — | | | | | | 5,316,493 | | | | | | — | | | | | | 1,560 | | | | | | — | | | | | | — | | | | | | 1,560 | | |
Net loss
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (8,367) | | | | | | (97) | | | | | | (8,464) | | |
Acquisition of non-controlling interests
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (192) | | | | | | — | | | | | | (754) | | | | | | (946) | | |
Balances as of January 1, 2020(*)
|
| | | | 7,229,885 | | | | | | 25,238 | | | | | | 39,804,163 | | | | | | — | | | | | | 16,494 | | | | | | (16,687) | | | | | | — | | | | | | (193) | | |
Exercise of Warrants to ordinary shares
|
| | | | — | | | | | | — | | | | | | 624,445 | | | | | | — | | | | | | 30 | | | | | | — | | | | | | — | | | | | | 30 | | |
Issuance of ordinary shares upon exercise of share options
|
| | | | — | | | | | | — | | | | | | 4,970 | | | | | | — | | | | | | 20 | | | | | | — | | | | | | — | | | | | | 20 | | |
Share-based compensation
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 596 | | | | | | — | | | | | | — | | | | | | 596 | | |
Issuance of series B Preferred shares, net
(**)
|
| | | | 6,509,301 | | | | | | 28,726 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Net loss
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (8,882) | | | | | | — | | | | | | (8,882) | | |
Balances as of December 31, 2020(*)
|
| | | | 13,739,186 | | | | | | 53,964 | | | | | | 40,433,578 | | | | | | — | | | | | | 17,140 | | | | | | (25,569) | | | | | | — | | | | | | (8,429) | | |
Exercise of Warrants to ordinary shares
|
| | | | — | | | | | | — | | | | | | 9,053 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Issuance of ordinary shares upon exercise of share options
|
| | | | — | | | | | | — | | | | | | 86,282 | | | | | | — | | | | | | 111 | | | | | | — | | | | | | — | | | | | | 111 | | |
Share-based compensation
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 812 | | | | | | — | | | | | | — | | | | | | 812 | | |
Net loss
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (27,271) | | | | | | — | | | | | | (27,271) | | |
Balances as of December 31, 2021(*)
|
| | | | 13,739,186 | | | | | $ | 53,964 | | | | | | 40,528,913 | | | | | $ | — | | | | | $ | 18,063 | | | | | $ | (52,840) | | | | | $ | — | | | | | $ | (34,777) | | |
| | |
Year ended December 31,
|
| |||||||||||||||
| | |
2019
|
| |
2020
|
| |
2021
|
| |||||||||
Cash flows from operating activities: | | | | | | | | | | | | | | | | | | | |
Net loss
|
| | | $ | (8,464) | | | | | $ | (8,882) | | | | | $ | (27,271) | | |
Adjustments to reconcile net loss to net cash used in operating activities: | | | | | | | | | | | | | | | | | | | |
Depreciation
|
| | | | 66 | | | | | | 86 | | | | | | 776 | | |
Share-based compensation
|
| | | | 546 | | | | | | 596 | | | | | | 812 | | |
(Increase) decrease in prepaid expenses and other receivables
|
| | | | (509) | | | | | | 283 | | | | | | 157 | | |
Increase in long term prepaid expenses
|
| | | | (16) | | | | | | (123) | | | | | | (1,889) | | |
Change in the fair value of warrants to convertible preferred shares
|
| | | | 994 | | | | | | 203 | | | | | | 13,257 | | |
Non-cash financial (income) expenses, net
|
| | | | 12 | | | | | | (153) | | | | | | 29 | | |
Increase in trade payables
|
| | | | 148 | | | | | | 114 | | | | | | 239 | | |
Increase in other payables and accrued expenses
|
| | | | 313 | | | | | | 625 | | | | | | 2,078 | | |
Net cash used in operating activities
|
| | | | (6,910) | | | | | | (7,251) | | | | | | (11,812) | | |
Cash flows from investing activities: | | | | | | | | | | | | | | | | | | | |
Investment in short-term deposits
|
| | | | (54,270) | | | | | | (70,200) | | | | | | (8,082) | | |
Redemption of short-term deposits
|
| | | | 45,400 | | | | | | 66,150 | | | | | | 30,282 | | |
Purchase of property and equipment
|
| | | | (1,293) | | | | | | (3,767) | | | | | | (2,927) | | |
Net cash (used in) provided by investing activities
|
| | | | (10,163) | | | | | | (7,817) | | | | | | 19,273 | | |
Cash flows from financing activities: | | | | | | | | | | | | | | | | | | | |
Proceeds from issuance of ordinary shares and warrants
|
| | | | 5,250 | | | | | | — | | | | | | — | | |
Proceeds from issuance of series B Preferred shares, net
|
| | | | — | | | | | | 28,726 | | | | | | — | | |
Proceeds from exercise of warrants
|
| | | | 1,019 | | | | | | 571 | | | | | | — | | |
Proceeds from exercise of options
|
| | | | — | | | | | | 20 | | | | | | 111 | | |
Acquisition of non-controlling interest
|
| | | | (946) | | | | | | — | | | | | | — | | |
Net cash provided by financing activities
|
| | | | 5,323 | | | | | | 29,317 | | | | | | 111 | | |
Effect of exchange rate changes on cash, cash equivalents and restricted cash
|
| | | | (18) | | | | | | 84 | | | | | | 108 | | |
(Decrease) increase in cash and cash equivalents and restricted cash
|
| | | | (11,768) | | | | | | 14,333 | | | | | | 7,680 | | |
Cash, cash equivalents and restricted cash at the beginning of the year
|
| | | | 13,609 | | | | | | 1,841 | | | | | | 16,174 | | |
Cash, cash equivalents and restricted cash at the end of the year
|
| | | $ | 1,841 | | | | | $ | 16,174 | | | | | $ | 23,854 | | |
Non-cash transactions: | | | | | | | | | | | | | | | | | | | |
Receivables from exercise of warrants to ordinary shares
|
| | | $ | 541 | | | | | $ | — | | | | | $ | — | | |
Supplemental disclosures of cash flow information: | | | | | | | | | | | | | | | | | | | |
Income tax payments
|
| | | $ | — | | | | | $ | 218 | | | | | $ | 103 | | |
Interest received
|
| | | $ | 780 | | | | | $ | 541 | | | | | $ | 351 | | |
| | |
December 31,
|
| |||||||||
| | |
2020
|
| |
2021
|
| ||||||
Cash and cash equivalents, as reported on the balance sheets
|
| | | $ | 15,598 | | | | | $ | 23,236 | | |
Restricted cash, as reported on the balance sheets
|
| | | | 576 | | | | | | 618 | | |
Cash, cash equivalents, and restricted cash, as reported in the statements of cash flows
|
| | | $ | 16,174 | | | | | $ | 23,854 | | |
| | |
%
|
|
Computers and software
|
| |
33
|
|
Laboratory equipment
|
| |
10 – 15
|
|
Furniture and office equipment
|
| |
7 – 15
|
|
Car
|
| |
20
|
|
Manufacturing equipment
|
| |
10
|
|
Leasehold improvements
|
| |
Over the shorter of the
term of the lease or its useful life |
|
| | |
Year Ended December 31,
|
| ||||||
| | |
2019
|
| |
2020
|
| |
2021
|
|
Expected term (years)
|
| |
5.4 – 7.1
|
| |
2.0 – 6.2
|
| |
5.0 – 6.3
|
|
Expected volatility
|
| |
85.3% – 88.6%
|
| |
90.8% – 102.1%
|
| |
85.5% – 89.2%
|
|
Risk-free interest rate
|
| |
1.9% – 2.6%
|
| |
0.1% – 0.5%
|
| |
0.8% – 1.4%
|
|
Expected dividend yield
|
| |
0%
|
| |
0%
|
| |
0%
|
|
| | |
December 31,
|
| |||||||||
| | |
2020
|
| |
2021
|
| ||||||
Government authorities
|
| | | $ | 472 | | | | | $ | 458 | | |
Prepaid expenses
|
| | | | 387 | | | | | | 227 | | |
Other receivables
|
| | | | 5 | | | | | | 22 | | |
| | | | $ | 864 | | | | | $ | 707 | | |
| | |
December 31,
|
| |||||||||
| | |
2020
|
| |
2021
|
| ||||||
Cost: | | | | | | | | | | | | | |
Manufacturing equipment(*)
|
| | | $ | 5,058 | | | | | $ | 7,238 | | |
Computers and software
|
| | | | 128 | | | | | | 394 | | |
Laboratory equipment
|
| | | | 251 | | | | | | 719 | | |
Furniture and office equipment
|
| | | | 37 | | | | | | 50 | | |
Cars
|
| | | | 57 | | | | | | 57 | | |
Leasehold improvements
|
| | | | 34 | | | | | | — | | |
| | | | | 5,565 | | | | | | 8,458 | | |
Accumulated depreciation
|
| | | | 170 | | | | | | 912 | | |
Depreciated cost
|
| | | $ | 5,395 | | | | | $ | 7,546 | | |
| | |
December 31,
|
| |||||||||
| | |
2020
|
| |
2021
|
| ||||||
Employees and payroll accruals
|
| | | $ | 525 | | | | | $ | 788 | | |
Accrued expenses
|
| | | | 551 | | | | | | 2,366 | | |
Related parties
|
| | | | 48 | | | | | | 48 | | |
| | | | $ | 1,124 | | | | | $ | 3,202 | | |
As of December 31, 2021
|
| | | | | | |
2022
|
| | | $ | 775 | | |
2023
|
| | | | 722 | | |
2024
|
| | | | 724 | | |
2025
|
| | | | 590 | | |
2026
|
| | | | 605 | | |
Thereafter
|
| | | | 4,948 | | |
| | | | $ | 8,364 | | |
| | |
December 31,
|
| |||||||||||||||
| | |
2019
|
| |
2020
|
| |
2021
|
| |||||||||
Expected term
|
| | | | 3 | | | | | | 2.25 | | | | | | 1.25 | | |
Expected dividend yield
|
| | | | 0% | | | | | | 0% | | | | | | 0% | | |
Expected volatility
|
| | | | 78.11% | | | | | | 96.83% | | | | | | 83.00% | | |
Risk-free interest rate
|
| | | | 1.91% | | | | | | 0.42% | | | | | | 0.75% | | |
| | |
2020
|
| |
2021
|
| ||||||
Beginning of year
|
| | | $ | 5,163 | | | | | $ | 5,366 | | |
Change in fair value
|
| | | | 203 | | | | | | 13,257 | | |
End of year
|
| | | $ | 5,366 | | | | | $ | 18,623 | | |
| | |
Year ended December 31,
|
| |||||||||||||||
| | |
2019
|
| |
2020
|
| |
2021
|
| |||||||||
Domestic (Israel)
|
| | | $ | 8,898 | | | | | $ | 9,322 | | | | | $ | 27,089 | | |
Foreign
|
| | | | (580) | | | | | | (598) | | | | | | 175 | | |
Total
|
| | | $ | 8,318 | | | | | $ | 8,724 | | | | | $ | 27,264 | | |
| | |
Year ended December 31,
|
| |||||||||||||||
| | |
2019
|
| |
2020
|
| |
2021
|
| |||||||||
Current: | | | | | | | | | | | | | | | | | | | |
Israel
|
| | | $ | — | | | | | $ | — | | | | | $ | — | | |
Foreign
|
| | | | 146 | | | | | | 158 | | | | | | 7 | | |
Total current income tax expense
|
| | | | 146 | | | | | | 158 | | | | | | 7 | | |
Deferred: | | | | | | | | | | | | | | | | | | | |
Domestic (Israel)
|
| | | | — | | | | | | — | | | | | | — | | |
Foreign
|
| | | | — | | | | | | — | | | | | | — | | |
Total deferred income tax expense
|
| | | | — | | | | | | — | | | | | | — | | |
Income tax expense
|
| | | $ | 146 | | | | | $ | 158 | | | | | $ | 7 | | |
| | |
December 31,
|
| |||||||||
| | |
2020
|
| |
2021
|
| ||||||
Reserves and allowances
|
| | | $ | 22 | | | | | $ | 18 | | |
R&D expenses
|
| | | | 482 | | | | | | 399 | | |
Intangible assets
|
| | | | 44 | | | | | | 31 | | |
Stock-based compensation
|
| | | | 134 | | | | | | 33 | | |
Loss carryforward
|
| | | | 1,551 | | | | | | 3,322 | | |
Deferred tax assets before valuation allowance
|
| | | | 2,233 | | | | | | 3,803 | | |
Less – valuation allowance
|
| | | | (2,233) | | | | | | (3,803) | | |
Net deferred tax assets
|
| | | $ | — | | | | | $ | — | | |
| | |
December 31, 2020
|
| |
December 31, 2021
|
| | | | | | | | | | | | | ||||||||||||||||||
| | |
Authorized
|
| |
Issued and
outstanding |
| |
Authorized
|
| |
Issued and
outstanding |
| |
Carrying
amount |
| |
Liquidation
preference |
| ||||||||||||||||||
| | |
Number of shares
|
| | | | | | | | | | | | | |||||||||||||||||||||
Series A Convertible Preferred shares
of no-par value(*) |
| | | | 16,295,256 | | | | | | 7,229,885 | | | | | | 16,295,256 | | | | | | 7,229,885 | | | | | $ | 25,238 | | | | | $ | 36,437 | | |
Series B Convertible Preferred shares
of no- par value(*) |
| | | | 9,052,920 | | | | | | 6,509,301 | | | | | | 9,052,920 | | | | | | 6,509,301 | | | | | | 28,726 | | | | | | 28,761 | | |
Total
|
| | | | 25,348,176 | | | | | | 13,739,186 | | | | | | 25,348,176 | | | | | | 13,739,186 | | | | | $ | 53,964 | | | | | $ | 65,198 | | |
| | |
December 31, 2020
|
| |
December 31, 2021
|
| ||||||||||||||||||
| | |
Authorized
|
| |
Issued and
outstanding |
| |
Authorized
|
| |
Issued and
outstanding |
| ||||||||||||
| | |
Number of shares
|
| |||||||||||||||||||||
Ordinary shares of no-par value(*)
|
| | | | 72,423,360 | | | | | | 40,433,578 | | | | | | 72,423,360 | | | | | | 40,528,913 | | |
Employees
|
| |
Year ended December 31, 2021
|
| |||||||||||||||||||||
|
Number
of options |
| |
Weighted
average exercise price |
| |
Aggregate
intrinsic value |
| |
Weighted
average remaining contractual life (years) |
| ||||||||||||||
Outstanding at beginning of year
|
| | | | 4,062,408 | | | | | $ | 3.40 | | | | | $ | 944,820 | | | | | | 7.78 | | |
Granted
|
| | | | 1,321,211 | | | | | $ | 9.81 | | | | | | | | | | | | | | |
Exercised
|
| | | | (4,809) | | | | | $ | 4.42 | | | | | | | | | | | | | | |
Forfeited and cancelled
|
| | | | (53,238) | | | | | $ | 5.16 | | | | | | | | | | | | | | |
Outstanding at end of year
|
| | | | 5,325,572 | | | | | $ | 4.97 | | | | | $ | 17,854,046 | | | | | | 7.42 | | |
Exercisable options
|
| | | | 3,233,657 | | | | | $ | 3.23 | | | | | $ | 14,184,527 | | | | | | 6.56 | | |
Service Providers
|
| |
Year ended December 31, 2021
|
| |||||||||||||||||||||
|
Number
of options |
| |
Weighted
average exercise price |
| |
Aggregate
intrinsic value |
| |
Weighted
average remaining contractual life (years) |
| ||||||||||||||
Outstanding at beginning of year
|
| | | | 662,006 | | | | | $ | 2.79 | | | | | $ | 313,200 | | | | | | 6.91 | | |
Granted
|
| | | | 140,667 | | | | | $ | 9.79 | | | | | | | | | | | | | | |
Exercised
|
| | | | (81,476) | | | | | $ | 1.10 | | | | | | | | | | | | | | |
Forfeited and cancelled
|
| | | | — | | | | | | | | | | | | | | | | | | | | |
Outstanding at end of year
|
| | | | 721,197 | | | | | $ | 4.34 | | | | | $ | 2,695,213 | | | | | | 6.61 | | |
Exercisable options
|
| | | | 580,745 | | | | | $ | 3.05 | | | | | $ | 2,649,873 | | | | | | 5.89 | | |
| | |
Number of RSU
|
| |||
Outstanding at beginning of year
|
| | | | — | | |
Granted
|
| | | | 1,036,850 | | |
Forfeited and cancelled
|
| | | | (5,600) | | |
Outstanding on December 31, 2021
|
| | | | 1,031,250 | | |
| | |
Year ended
December 31, |
| |||||||||||||||
| | |
2019
|
| |
2020
|
| |
2021
|
| |||||||||
Research and development
|
| | | $ | 380 | | | | | $ | 372 | | | | | $ | 654 | | |
Marketing expenses
|
| | | | 18 | | | | | | 20 | | | | | | 7 | | |
General and administrative
|
| | | | 148 | | | | | | 204 | | | | | | 151 | | |
Total share-based compensation expense
|
| | | $ | 546 | | | | | $ | 596 | | | | | $ | 812 | | |
| | |
Year ended December 31,
|
| |||||||||||||||
| | |
2019
|
| |
2020
|
| |
2021
|
| |||||||||
Financial expenses: | | | | | | | | | | | | | | | | | | | |
Foreign currency transaction loss, net
|
| | | $ | 79 | | | | | $ | — | | | | | $ | 412 | | |
Remeasurement of warrants
|
| | | | 994 | | | | | | 203 | | | | | | 13,257 | | |
Others
|
| | | | 11 | | | | | | 14 | | | | | | 16 | | |
Total financial expenses
|
| | | | 1,084 | | | | | | 217 | | | | | | 13,685 | | |
| | |
Year ended December 31,
|
| |||||||||||||||
| | |
2019
|
| |
2020
|
| |
2021
|
| |||||||||
Financial income: | | | | | | | | | | | | | | | | | | | |
Foreign currency transaction profit, net
|
| | | | — | | | | | | 101 | | | | | | — | | |
Interest from deposits
|
| | | | 776 | | | | | | 613 | | | | | | 211 | | |
Others
|
| | | | — | | | | | | 23 | | | | | | — | | |
Total financial income
|
| | | | 776 | | | | | | 737 | | | | | | 211 | | |
Financial expenses (income), net
|
| | | $ | 308 | | | | | $ | (520) | | | | | $ | 13,474 | | |
|
| | |
Year ended December 31,
|
| |||||||||||||||
| | |
2019
|
| |
2020
|
| |
2021
|
| |||||||||
Numerator: | | | | | | | | | | | | | | | | | | | |
Net loss attributable to Ordinary shareholders
|
| | | $ | (8,367) | | | | | $ | (8,882) | | | | | $ | (27,271) | | |
Denominator: | | | | | | | | | | | | | | | | | | | |
Weighted-average shares used in computing net loss per share attributable to ordinary shareholders, basic and diluted
|
| | | | 33,815,448 | | | | | | 40,274,935 | | | | | | 40,534,697 | | |
Net loss per share attributable to ordinary shareholders, basic and diluted
|
| | | | (0.25) | | | | | | (0.22) | | | | | | (0.67) | | |
| | |
Year ended December 31,
|
| |||||||||||||||
| | |
2019
|
| |
2020
|
| |
2021
|
| |||||||||
Convertible preferred shares
|
| | | | 7,229,885 | | | | | | 13,739,186 | | | | | | 13,739,186 | | |
Outstanding share options
|
| | | | 4,371,668 | | | | | | 4,724,414 | | | | | | 6,046,769 | | |
RSU
|
| | | | — | | | | | | — | | | | | | 1,031,250 | | |
Warrant to Preferred A shares
|
| | | | 3,614,960 | | | | | | 3,880,777 | | | | | | 3,880,777 | | |
Warrants
|
| | | | 8,436,578 | | | | | | 651,067 | | | | | | 651,067 | | |
| | | | | 23,653,091 | | | | | | 22,995,444 | | | | | | 25,349,049 | | |
| | |
December 31,
|
| |||||||||
| | |
2020
|
| |
2021
|
| ||||||
Israel
|
| | | $ | 3,540 | | | | | $ | 5,842 | | |
United States
|
| | | | 1,855 | | | | | | 1,699 | | |
Japan
|
| | | | — | | | | | | 5 | | |
Total property and equipment, net
|
| | | $ | 5,395 | | | | | $ | 7,546 | | |
| | | | ||
| Financial Statements: | | | | |
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | |
| | |
December 31,
2021 |
| |
December 31,
2020 |
| ||||||
ASSETS | | | | | | | | | | | | | |
Current assets | | | | | | | | | | | | | |
Cash
|
| | | $ | 556,494 | | | | | $ | — | | |
Total Current Assets
|
| | | | 556,494 | | | | | | — | | |
Deferred offering costs
|
| | | | — | | | | | | 165,029 | | |
Marketable securities held in Trust Account
|
| | | | 275,016,417 | | | | | | — | | |
TOTAL ASSETS
|
| | | $ | 275,572,911 | | | | | $ | 165,029 | | |
LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY
|
| | | | | | | | | | | | |
Current liabilities
|
| | | | | | | | | | | | |
Accrued expenses
|
| | | $ | 893,937 | | | | | $ | 1,374 | | |
Accrued offering costs
|
| | | | — | | | | | | 50,175 | | |
Due to related parties
|
| | | | — | | | | | | 89,854 | | |
Total Current Liabilities
|
| | | | 893,937 | | | | | | 141,403 | | |
Deferred underwriting fee payable
|
| | | | 10,325,000 | | | | | | — | | |
Warrant liability
|
| | | | 10,137,500 | | | | | | — | | |
Total Liabilities
|
| | | | 21,356,437 | | | | | | 141,403 | | |
Commitments and Contingencies
|
| | | | | | | | | | | | |
Class A common stock, $.0001 par value; 100,000,000 shares authorized; 27,500,000 and no shares subject to possible redemption issued and outstanding at redemption value at December 31, 2021 and 2020, respectively
|
| | | | 275,000,000 | | | | | | — | | |
Stockholders’ (Deficit) Equity
|
| | | | | | | | | | | | |
Class B common stock, $0.0001 par value; 10,000,000 shares authorized; 6,875,000 and 6,900,000 shares issued and outstanding at December 31, 2021 and 2020, respectively
|
| | | | 687 | | | | | | 690 | | |
Additional paid-in capital
|
| | | | — | | | | | | 24,310 | | |
Accumulated deficit
|
| | | | (20,784,213) | | | | | | (1,374) | | |
Total Stockholders’ (Deficit) Equity
|
| | | | (20,783,526) | | | | | | 23,626 | | |
TOTAL LIABILITIES AND STOCKHOLDERS’
(DEFICIT) EQUITY |
| | | $ | 275,572,911 | | | | | $ | 165,029 | | |
| | |
Year Ended
December 31, 2021 |
| |
For the
Period from August 18, 2020 (Inception) through December 31, 2020 |
| ||||||
Formation and operating costs
|
| | | $ | 1,929,742 | | | | | $ | 1,374 | | |
Loss from operations
|
| | | | (1,929,742) | | | | | | (1,374) | | |
Other income (expense):
|
| | | | | | | | | | | | |
Change in fair value of warrants
|
| | | | 12,192,500 | | | | | | — | | |
Transaction costs allocated to warrant liabilities
|
| | | | (850,929) | | | | | | — | | |
Fair value of warrant liability in excess of purchase price paid for Private Placement Warrants
|
| | | | (680,000) | | | | | | — | | |
Interest earned on marketable securities held in Trust Account
|
| | | | 16,417 | | | | | | — | | |
Other income, net
|
| | | | 10,677,988 | | | | | | — | | |
Net income (loss)
|
| | | $ | 8,748,246 | | | | | $ | (1,374) | | |
Weighted average shares outstanding of Class A common stock
|
| | | | 25,993,151 | | | | | | — | | |
Basic and diluted net income per share, redeemable Class A common stock
|
| | |
$
|
0.27
|
| | | | $ | — | | |
Weighted average shares outstanding of Class B common stock
|
| | | | 6,827,055 | | | | | | 6,250,000 | | |
Basic net income (loss) per share, Class B common stock
|
| | | $ | 0.27 | | | | | $ | (0.00) | | |
Weighted average shares outstanding of Class B common stock
|
| | | | 6,875,000 | | | | | | — | | |
Diluted net income per share, Class B common stock
|
| | |
$
|
0.27
|
| | | | $ | — | | |
| | |
Class A
Common Stock |
| |
Class B
Common Stock |
| |
Additional
Paid-in Capital |
| |
Accumulated
Deficit |
| |
Total
Stockholders’ Equity (Deficit) |
| |||||||||||||||||||||||||||
| | |
Shares
|
| |
Amount
|
| |
Shares
|
| |
Amount
|
| ||||||||||||||||||||||||||||||
Balance – August 18, 2020 (Inception)
|
| | | | — | | | | |
$
|
—
|
| | | | | — | | | | | $ | — | | | | | $ | — | | | | | $ | — | | | | | $ | — | | |
Issuance of Class B common stock to Sponsor
|
| | |
|
—
|
| | | |
|
—
|
| | | | | 6,900,000 | | | | | | 690 | | | | | | 24,310 | | | | | | — | | | | | | 25,000 | | |
Net loss
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (1,374) | | | | | | (1,374) | | |
Balance – December 31, 2020
|
| | | | — | | | | | $ | — | | | | | | 6,900,000 | | | | | $ | 690 | | | | | | 24,310 | | | | | | (1,374) | | | | | | 23,626 | | |
Remeasurement Adjustment on redeemable common stock
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (24,313) | | | | | | (29,531,085) | | | | | | (29,555,398) | | |
Forfeiture of Founder Shares
|
| | | | — | | | | | | — | | | | | | (25,000) | | | | | | (3) | | | | | | 3 | | | | | | — | | | | | | — | | |
Net income
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 8,748,246 | | | | | | 8,748,246 | | |
Balance – December 31, 2021
|
| | | | — | | | | | $ | — | | | | |
|
6,875,000
|
| | | |
$
|
687
|
| | | | $ | — | | | | |
$
|
(20,784,213)
|
| | | |
$
|
(20,783,526)
|
| |
| | |
Year Ended
December 31, 2021 |
| |
For the Period
from August 18, 2020 (Inception) through December 31, 2020 |
| ||||||
Cash Flows from Operating Activities: | | | | | | | | | | | | | |
Net income (loss)
|
| | | $ | 8,748,246 | | | | | $ | (1,374) | | |
Adjustments to reconcile net income (loss) to net cash used in operating activities:
|
| | | | | | | | | | | | |
Change in fair value of warrants
|
| | | | (12,192,500) | | | | | | — | | |
Transaction costs allocated to warrant liabilities
|
| | | | 850,929 | | | | | | — | | |
Fair Value of Warrant Liability in excess of Purchase Price
|
| | | | 680,000 | | | | | | — | | |
Interest earned on marketable securities held in Trust Account
|
| | | | (16,417) | | | | | | — | | |
Changes in operating assets and liabilities:
|
| | | | | | | | | | | | |
Accrued expenses
|
| | | | 892,563 | | | | | | 1,374 | | |
Net cash used in operating activities
|
| | |
|
(1,037,179)
|
| | | | | — | | |
Cash Flows from Investing Activities: | | | | | | | | | | | | | |
Investment of cash in Trust Account
|
| | | | (275,000,000) | | | | | | — | | |
Net cash used in investing activities
|
| | |
|
(275,000,000)
|
| | | | | — | | |
Cash Flows from Financing Activities: | | | | | | | | | | | | | |
Proceeds from sale of Units, net of underwriting discounts paid
|
| | | | 270,200,000 | | | | | | — | | |
Proceeds from sale of Private Placement Warrants
|
| | | | 6,800,000 | | | | | | — | | |
Proceeds from promissory note – related party
|
| | | | 258 | | | | | | 89,854 | | |
Repayment of promissory note – related party
|
| | | | (90,112) | | | | | | (89,854) | | |
Payments of offering costs
|
| | | | (316,473) | | | | | | — | | |
Net cash provided by financing activities
|
| | |
|
276,593,673
|
| | | | | — | | |
Net Change in Cash
|
| | |
|
556,494
|
| | | | | — | | |
Cash – Beginning
|
| | | | — | | | | | | — | | |
Cash – Ending | | | | $ | 556,494 | | | | |
$
|
—
|
| |
Non-cash investing and financing activities: | | | | | | | | | | | | | |
Offering costs included in accrued offering costs
|
| | | $ | — | | | | | $ | 50,175 | | |
Offering costs paid by Sponsor in exchange for issuance of Founder Shares
|
| | | $ | — | | | | | $ | 25,000 | | |
Remeasurement adjustment on redeemable common stock
|
| | | $ | 29,555,398 | | | | | $ | — | | |
Deferred underwriting fee payable
|
| | | $ | 10,325,000 | | | | | $ | — | | |
Initial classification of warrant liability
|
| | | $ | 22,330,000 | | | | | $ | — | | |
Forfeiture of Founder Shares
|
| | | $ | (3) | | | | | $ | — | | |
|
Gross proceeds
|
| | | $ | 275,000,000 | | |
| Less: | | | | | | | |
|
Proceeds allocated to Public Warrants
|
| | | | (14,850,000) | | |
|
Class A common stock issuance costs
|
| | | | (14,705,398) | | |
| Plus: | | | | | | | |
|
Accretion of carrying value to redemption value
|
| | | | 29,555,398 | | |
|
Class A common stock subject to possible redemption
|
| | | $ | 275,000,000 | | |
| | |
Year Ended
December 31, 2021 |
| |
For the Period from
August 18, 2020 (Inception) Through December 31, 2020 |
| ||||||||||||||||||
| | |
Class A
|
| |
Class B
|
| |
Class A
|
| |
Class B
|
| ||||||||||||
Basic net income (loss) per common stock | | | | | | | | | | | | | | | | | | | | | | | | | |
Numerator: | | | | | | | | | | | | | | | | | | | | | | | | | |
Allocation of net income (loss), as adjusted
|
| | | $ | 6,928,490 | | | | | $ | 1,819,756 | | | | | $ | — | | | | | $ | (1,374) | | |
Denominator: | | | | | | | | | | | | | | | | | | | | | | | | | |
Basic weighted average shares outstanding
|
| | | | 25,993,151 | | | | | | 6,827,055 | | | | | | — | | | | | | 6,250,000 | | |
Basic net income per common stock
|
| | | $ | 0.27 | | | | | $ | 0.27 | | | | | $ | — | | | | | $ | (0.00) | | |
| | |
Year Ended
December 31, 2021 |
| |
For the Period from
August 18, 2020 (Inception) Through December 31, 2020 |
| ||||||||||||||||||
| | |
Class A
|
| |
Class B
|
| |
Class A
|
| |
Class B
|
| ||||||||||||
Diluted net income per common stock | | | | | | | | | | | | | | | | | | | | | | | | | |
Numerator: | | | | | | | | | | | | | | | | | | | | | | | | | |
Allocation of net income, as adjusted
|
| | | $ | 6,928,490 | | | | | $ | 1,829,862 | | | | | $ | — | | | | | $ | — | | |
Denominator: | | | | | | | | | | | | | | | | | | | | | | | | | |
Diluted weighted average shares outstanding
|
| | | | 25,993,151 | | | | | | 6,875,000 | | | | | | — | | | | | | — | | |
Diluted net income per common stock
|
| | | $ | 0.27 | | | | | $ | 0.27 | | | | | $ | — | | | | | $ | — | | |
| | |
December 31,
2021 |
| |
December 31,
2020 |
| ||||||
Deferred tax assets: | | | | | | | | | | | | | |
Net operating loss carryforward
|
| | | $ | 38,737 | | | | | $ | 289 | | |
Start-up and organizational costs
|
| | | | 274,984 | | | | | | — | | |
Total deferred tax assets
|
| | | | 313,721 | | | | | | 289 | | |
Valuation Allowance
|
| | | | (313,721) | | | | | | (289) | | |
Net deferred tax assets
|
| | | $ | — | | | | | $ | — | | |
| | |
December 31,
2021 |
| |
December 31,
2020 |
| ||||||
Federal | | | | | | | | | | | | | |
Current
|
| | | $ | — | | | | | $ | — | | |
Deferred
|
| | | | (313,432) | | | | | | (289) | | |
State and Local | | | | | | | | | | | | | |
Current
|
| | | | — | | | | | | — | | |
Deferred
|
| | | | — | | | | | | — | | |
Change in valuation allowance
|
| | | | 313,432 | | | | | | 289 | | |
Income tax provision
|
| | | $ | — | | | | | $ | — | | |
| | |
December 31,
2021 |
| |
December 31,
2020 |
| ||||||
Statutory federal income tax rate
|
| | | | 21.0% | | | | | | 21.0% | | |
Change in fair value of warrants
|
| | | | (29.3)% | | | | | | 0.0% | | |
Transaction costs allocated to warrant liabilities
|
| | | | 2.0% | | | | | | 0.0% | | |
Fair value of warrant liability in excess of purchase price paid for Private Placement Warrants
|
| | | | 1.6% | | | | | | 0.0% | | |
Facilitative Merger Costs
|
| | | | 1.0% | | | | | | | | |
Valuation allowance
|
| | | | 3.6% | | | | | | (21.0)% | | |
Income tax provision
|
| | | | 0.0% | | | | | | 0.0% | | |
Description
|
| |
Level
|
| |
December 31,
2021 |
| |
December 31,
2020 |
| |||||||||
Assets: | | | | | | | | | | | | | | | | | | | |
Marketable securities held in Trust Account – U.S. Treasury Securities
Money Market Fund |
| | | | 1 | | | | | $ | 275,016,417 | | | | |
$
|
—
|
| |
Liabilities: | | | | | | | | | | | | | | | | | | | |
Warrant liability – Public Warrants
|
| | | | 1 | | | | | | 6,737,500 | | | | |
|
—
|
| |
Warrant liability – Private Placement Warrants
|
| | | | 3 | | | | | | 3,400,000 | | | | |
|
—
|
| |
Input
|
| |
January 20,
2021 (Initial Measurement) |
| |||
Risk-free interest rate
|
| | | | 0.62% | | |
Trading days per year
|
| | | | 250 | | |
Expected volatility
|
| | | | 16.4% | | |
Exercise price
|
| | | $ | 11.50 | | |
Stock Price
|
| | | $ | 9.46 | | |
Input
|
| |
December 31,
2021 |
| |||
Risk-free interest rate
|
| | | | 1.27% | | |
Trading days per year
|
| | | | 250 | | |
Expected volatility
|
| | | | 9.7% | | |
Exercise price
|
| | | $ | 11.50 | | |
Stock price
|
| | | $ | 9.82 | | |
| | |
Private
Placement Warrants |
| |
Public
Warrants |
| |
Warrant
Liabilities |
| |||||||||
Fair value as of January 1, 2021
|
| | | $ | — | | | | | $ | — | | | | | $ | — | | |
Initial measurement on January 20, 2021
|
| | | | 7,480,000 | | | | | | 14,850,000 | | | | | | 22,330,000 | | |
Change in fair value
|
| | | | (3,196,000) | | | | | | (6,187,500) | | | | | | (9,383,500) | | |
Transfer to Level 1
|
| | |
|
—
|
| | | | | (8,662,500) | | | | | | (8,662,500) | | |
Fair value as of March 31, 2021
|
| | | $ | 4,284,000 | | | | |
$
|
—
|
| | | | $ | 4,284,000 | | |
Change in fair value
|
| | | | 816,000 | | | | |
|
—
|
| | | | | 816,000 | | |
Fair value as of June 30, 2021
|
| | | | 5,100,000 | | | | |
|
—
|
| | | | | 5,100,000 | | |
Change in fair value
|
| | | | (340,000) | | | | |
|
—
|
| | | | | (340,000) | | |
Fair value as of September 30, 2021
|
| | | $ | 4,760,000 | | | | |
$
|
—
|
| | | | $ | 4,760,000 | | |
Change in fair value
|
| | | | (1,360,000) | | | | |
|
—
|
| | | | | (1,360,000) | | |
Fair value as of December 31, 2021
|
| | | $ | 3,400,000 | | | | |
$
|
—
|
| | | | $ | 3,400,000 | | |
| | | | | | |
Incorporation by Reference
|
| ||||||||||||
|
Exhibit
No. |
| |
Description
|
| |
Form
|
| |
File No.
|
| |
Exhibit
No. |
| |
Filing
Date |
| |
Filed /
Furnished Herewith |
|
| 2.1† | | | | |
F-4
|
| |
333-258915
|
| |
2.1
|
| |
August 19, 2021
|
| | | | |
| 3.1 | | | | |
20-F
|
| |
001-41316
|
| | | | |
March 28, 2022
|
| | | | |
| 4.1 | | | | |
F-4
|
| |
333-258915
|
| |
4.5
|
| |
January 5, 2022
|
| | | | |
| 4.2† | | | | |
F-4
|
| |
333-258915
|
| |
4.8
|
| |
December 1, 2021
|
| | | | |
| 5.1 | | | | |
F-1
|
| |
333-264306
|
| |
5.1
|
| |
April 15, 2022
|
| | | | |
| 10.1 | | | | |
F-4
|
| |
333-258915
|
| |
10.3
|
| |
August 19, 2021
|
| | | | |
| 10.2 | | | | |
F-4
|
| |
333-258915
|
| |
10.4
|
| |
August 19, 2021
|
| | | | |
| 10.3 | | | Amendment to Sponsor Support Agreement, dated as of February 17, 2022, by and among Healthcare Capital Sponsor LLC, Healthcare Capital Corp., Alpha Tau Medical Ltd. and the individuals named on the signature pages thereto. | | |
20-F
|
| |
001-41316
|
| |
4.8
|
| |
March 28, 2022
|
| | | |
| 10.4 | | | | |
F-4
|
| |
333-258915
|
| |
10.6
|
| |
August 19, 2021
|
| | | | |
| 10.5†† | | | | |
F-4
|
| |
333-258915
|
| |
10.7
|
| |
August 19, 2021
|
| | | | |
| 10.6†† | | | | |
F-4
|
| |
333-258915
|
| |
10.8
|
| |
December 1, 2021
|
| | | |
| | | | | | |
Incorporation by Reference
|
| ||||||||||||
|
Exhibit
No. |
| |
Description
|
| |
Form
|
| |
File No.
|
| |
Exhibit
No. |
| |
Filing
Date |
| |
Filed /
Furnished Herewith |
|
| 10.7†† | | | | |
F-4
|
| |
333-258915
|
| |
10.9
|
| |
December 1, 2021
|
| | | | |
| 10.8 | | | | |
F-4
|
| |
333-258915
|
| |
10.10
|
| |
December 1, 2021
|
| | | | |
| 10.9 | | | | |
F-4
|
| |
333-254790
|
| |
10.11
|
| |
December 1, 2021
|
| | | | |
| 10.10 | | | | |
20-F
|
| |
001-41316
|
| |
4.8
|
| |
March 28, 2022
|
| | | | |
| 21.1 | | | | |
20-F
|
| |
001-41316
|
| |
8.1
|
| |
March 28, 2022
|
| | | | |
| 23.1 | | | Consent of Kost, Forer, Gabbay & Kasierer, a member of Ernst & Young Global, independent registered accounting firm for Alpha Tau Medical Ltd. | | | | | | | | | | | | | | |
*
|
|
| 23.2 | | | Consent of Marcum LLP, independent registered public accounting firm for Healthcare Capital Corp. | | | | | | | | | | | | | | |
*
|
|
| 23.3 | | | | |
F-1
|
| |
333-264306
|
| |
23.3
|
| |
April 15, 2022
|
| | | | |
| 24.1 | | | | |
F-1
|
| |
333-264306
|
| |
24.1
|
| |
April 15, 2022
|
| | | | |
| 101.INS | | |
Inline XBRL Instance Document
|
| | | | | | ||||||||||
| 101.SCH | | | Inline XBRL Taxonomy Extension Schema Document | | | | | | | ||||||||||
| 101.CAL | | | Inline XBRL Taxonomy Extension Calculation Linkbase Document | | | | | | | ||||||||||
| 101.DEF | | | Inline XBRL Taxonomy Extension Definition Linkbase Document | | | | | | | ||||||||||
| 101.LAB | | | Inline XBRL Taxonomy Extension Label Linkbase Document 101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase | | | | | | | ||||||||||
| 104 | | | Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101) | | | | | | | ||||||||||
| 107 | | | | |
F-1
|
| |
333-264306
|
| |
107
|
| |
April 15, 2022
|
| | | |
|
NAME
|
| |
POSITION
|
| |
DATE
|
|
|
/s/ Uzi Sofer
Uzi Sofer
|
| |
Chief Executive Officer and Chairman
(Principal Executive Officer) |
| |
May 3, 2022
|
|
|
/s/ Raphi Levy
Raphi Levy
|
| |
Chief Financial Officer
(Principal Financial Officer and Principal Accounting Officer) |
| |
May 3, 2022
|
|
|
*
Ruti Alon
|
| | Director | | |
May 3, 2022
|
|
|
*
Michael Avruch
|
| | Director | | |
May 3, 2022
|
|
|
*
S. Morry Blumenfeld, Ph.D.
|
| | Director | | |
May 3, 2022
|
|
|
*
Meir Jakobsohn
|
| | Director | | |
May 3, 2022
|
|
|
*
Alan Adler
|
| | Director | | |
May 3, 2022
|
|
|
NAME
|
| |
POSITION
|
| |
DATE
|
|
|
*
Gary Leibler
|
| | Director | | |
May 3, 2022
|
|
|
*
Peter Melnyk
|
| | Director | | |
May 3, 2022
|
|
|
*
David Milch
|
| | Director | | |
May 3, 2022
|
|
|
By:
/s/ Raphi Levy
Name: Raphi Levy
Title: Attorney-in-fact |
| | | | | | |
1 Year Alpha Tau Medical Chart |
1 Month Alpha Tau Medical Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions